HBM HOLDINGS-B (02142.HK): Expected Profit of USD62 Million–USD67 Million for H1 2026; Revenue Stood at Approximately USD101 Million in Corresponding Period Last Year

NewTimeSpace News: On 24 July 2026, HBM Holdings Limited (02142.HK) released a positive profit alert. Based on preliminary review of unaudited management accounts for the six months ended 30 June 2026, the Group expects revenue to range from approximately USD120 million (HK$941 million) to USD125 million (HK$980 million), compared with USD101 million in the same period of last year. Expected profit stands between USD62 million (HK$486 million) and USD67 million (HK$525 million), while total adjusted profit is anticipated to reach USD70 million–USD75 million.

Revenue growth and profitable scale are mainly attributable to the following factors: sustained strategic cooperation with world-leading multinational pharmaceutical companies, such as the long-term strategic partnership with AstraZeneca and global collaboration with Bristol Myers Squibb; out-licensing and collaboration of innovative assets, including the licensing deal with Solstice Oncology and milestone payments triggered by progress of previous out-licensed programmes; robust expansion of antibody-related businesses at NovamAb, comprising income generated from antibody transactions and antibody discovery services.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.